1259
PŘEHLEDOVÉ42522701004388130181216258306358404446
ČLÁNKY88722701003973122176223272
Léčba4253370100316698136171
tří6123370100265167
pacientů69533701003773103118154191218257
s968337010028
Erdheimovou-Chesterovou101233701004064101139174190249288324362400426466504539569596631656694730768806
chorobou183433701003067106131169208247285
kladribinem,21353370100335085123147163201216254290350365
případně25163370100376178116151189227262
kombinací279533701003371131169184222257287303
kladribinu31143370100335084123147163201216254292
a3422337010034
cyklofosfamidu347233701002967102119157177216245266302362377415453
a3941337010034
přehled39913370100376197134150185224
léčby42313370100155081120155
této44023370100266188126
nemoci454433701003773133172202218
16419822701002870113
|326227010043
VNITŘNÍ4268043010746106127172220280301
LÉKAŘSTVÍ748804301074185130188236280325378400
/11688043010757
Vnitř12458043010771118137165191
Lék1456804301074083122
2021;1597804301074487129168178
67(3):1794804301074486106148169184
157–1641997804301074482124165203243289
/23058043010777
www.casopisvnitrnilekarstvi.cz442680430107651332012142542953293774274464795215705896176436927117307748128548809159449871007102310631101
40.425553085367489
Tezol529554083326393130146
O,6905540834758
Citak763554083395577110140
EC,918554083327386
Ayhan10195540834070109141179
YS12145540833467
et12965540833456
al.1367554083314760
Effective1442554083325170104137161176209243
High-dose1701554083435897135158198236263298
Interferon-α2014554083145274108129150185206243282304344
Therapy23735540833271106128161200231
in26195540831452
a268755408331
13-Year-Old2733554083346486119150425654083325373124140180
Girl620654083496587103
With7386540836380102141
Erdheim-Chester895654083385997136171186245268311349385412435469491
Disease.1401654083516793129161188223236
J165265408330
Pediatr16976540834175115130163185206
Hematol19196540835085144176198236252
Oncol21866540835392125162178
2019.23806540833974106136148
doi:2543654083448298110
10.1097/2669654083407184115147183216236
MPH.0000000000001538.4257540835490134147183219255291327363399435472508544580612642675709723
41.425853085366981
Aouba5218540834481120159192
A,7288540834458
Georgin-Lavialle8018540834782121142181196234256289323354370402417432467
S,12848540833547
Pagnoux13478540833870109147185223254
C161785408342
et16758540833659
al.1749854083345063
Rationale1827854083387193108146184217232267
and21098540833573112
efficacy223685408337557391123156188221
of24738540834059
interleukin-12547854083185677111132148183221251267305327358
targeting425954083225476114149171186224263
in7039540831553
Erdheim-Chester771954083335492130165180238260303341376403426460481
disease.1267954083385480115146173208220
Blood1503954083355189127167
2010;16859540833569100132145
116(20):1845954083346293112146180198210
4070–4076.20719540833470102135173210246279311324
42.4251053085367086
Podestà52610540833369108143170193225
MA,76610540835294108
Graziani8891054083416295124140171209224
G,112810540834154
Reggiani119710540833368107146161193230245
F1457105408330
et150210540833154
al.15711054083294457
Improvement164310540831270108130167198232290325363384
of204210540833554
Erdheim-Chester21111054083305188126161176233255298335370397420453474
disease-related260010540833651771111431692042272492824251154083154768102141
renal5821154083185290122137
failure734115408316496480117138172
after9211154083294873107128
treatment10641154083194074106128186220258280
with13591154083486386124
anakinra.14981154083296799129146183204237250
Kidney17641154083324887125160191
Res19701154083336895
Clin20801154083375267105
Pract22001154083335386118142
2014;23571154083326697128140
33(3):25121154083326583116133145
165–167.26721154083326397133163194227233
43.4251253085367186
Szturz5261254083305983121142172
P,71312540833337
Adam76612540833876108166
Z,94712540833548
Rehák101012540833368106138168
Z1193125408335
et124312540833254
al.13121254083304558
Xanthelasma138512540833567105127164199215247273330362
palpebrarum17631254083366984122158197218251272310367
responding21461254083185278117156194233248285324
to248512540831956
interleukin-125561254083125071105126142176214244260298320350
blockade.4251354083395593125155189228263275
Intern7151354083155375108130168
Med89913540835489129
J1043135408324
2014;108313540833468100131142
44(6):12411354083347190124142154
617–618.14101354083346494126163194225238
44.4251453085367490
Darstein53014540834981102130153187202240
F,78514540833642
Kirschey8421454083385576103135173208240
S,109714540833649
Heckl116114540834883115145162
S1338145408336
et139014540833759
al.14651454083355063
Successful154314540833674106137170197224244282298
treatment18561454083254781113134192228266287
of215814540834160
Erdheim-Chester22341454083365795133168183241263306344379406429463484
disease2733145408342578311815042515540832661
with5011554083516789127
combination64415540833168126166181219251273288326365
of102415540833857
interleukin-1-targeting10961554083155375108130145180218248265302325356374397430451489524546561599638
drugs17501554083385997136163
and192815540833270109
high-dose20521554083385392130152193231258293
glucocorticoids.23601554083385491123160193230251276291323360376415441454
Intern2830155408315534251654083225577115
Med55616540835489129
J700165408324
2014;73916540833569100132143
44(1):8981654083347190122136148
90–92.106216540833470108142175188
45.4251753085367185
Courcoul52517540833774112133163200238253
A,79317540833852
Vignot8601754083334987125163185
E,106017540833042
Chapurlat111817540833774106145183204219251272
R.140617540833246
Successful14681754083296698129162188215234273288
treatment17711754083194074105127184219257278
of206417540833554
Erdheim-Chester21331754083305088126160175232254297334369395418452473
disease26211754083355076110142168203
by283917540833667
interleukin-14251854083155374108129145180217248264302324355
receptor7951854083215588122161183220241
antagonist10521854083316991124163201239255281304
protein.13711854083396098120153168206220
Joint16061854083246278116137
Bone175818540833674113148
Spine19211854083337187125160
2014;209618540833468100131143
81(2):22541854083356681115133145
175–177.24151854083346396132163192227233
46.4251953085367489
Killu530195408340567287124
AM,669195408346102115
Liang7991954083365284122161
JJ,9751954083295365
Jaffe10551954083296181100134
AS.12051954083457993
Erdheim-Chester13131954083375896134169184242265307345380407430464485
disease18141954083425784119150177212
with20411954083567194132
cardiac21881954083366990128143175208
involvement24111954083195788126142174209266302340361
successfully2788195408330681004252054083316592118138177192207239
treated6792054083224478109131165205
with8992054083506688127
anakinra.104120540833270102132149187208241254
Int13102054083155375
J1400205408324
Cardiol14392054083407394132148186201
2013;165620540833468100130141
167(5):18122054083356699115149167179
e115–117.20062054083346492122158189216246252
47.4252153085367079
Aubert51921540834380119154176200
O,73421540834960
Aouba80921540834280118157190
A,101421540834357
Deshayes108621540834782109147179210244271
S1372215408334
et142121540833658
al.14942154083334961
Favorable15712154083336394132154187226242277
radiological18632154083225594109147163201241256288320336
outcome22142154083397799130167225260
of249021540833857
skeletal25632154083275791107142164197212
Erdheim-Chester279021540833455934252254083387388145168211249284310334367389
disease8292254083385379114146173208
involvement10522254083155284121137170204262297335357
with14242254083506688127
anakinra.156622540833270102132149187208241254
Joint18352254083246378116138
Bone198822540833574112147
Spine21512254083327186124159
2013;232622540833468100130141
80(2):24822254083347089123141153
206–207.265022540833569104142174208240247
48.4252353085367490
Tran5302354083365386124
TA,6692354083357387
Pariente7712354083387091107141179201235
D,102123540834859
Lecron109523540833468101122160198
JC130823540832768
et139123540833759
al.14662354083345063
Treatment15442354083355286118140198233271293
of185223540834060
pediatric192723540834177116131163185207222254
Erdheim-Chester21972354083355694132167182240262305343378405428462483
disease26952354083415682117149176211
with4252454083516689127
interleukin-1-targeting5672454083155374108129145180218248264302324355374396429450488523546561599638
drugs.12202454083385998137163176
Arthritis14122454083416287125146162184199225
Rheum165324540833573108146204
2011;187224540833569100128136
63(12):20242454083346886117147165177
4031–4032.221624540833570104135167204240273306318
49.4252553085367184
Cohen-Aubart52425540833774112146184206246283321354374399
F,93825540832935
Maksud98825540835183113141178216
P,121925540833337
Saadoun12712554083306294132170207245
D1531255408342
et158825540833153
al.16562554083294456
Variability17272554083336485100131170185200215237270
in201225540831249
the20762554083195791
efficacy2182255408331496784116148180213
of241025540833453
the24782554083195791
IL125842554083124473
receptor26722554083185183117155177213234
antagonist4252654083327091124163201240255281304
anakinra74426540833068100131147185206239
for9982654083175476
treating10892654083204175107129144182221
Erdheim-Chester13252654083315290128163178236258301339374401424458479
disease.18192654083365177112144171206218
Blood20522654083344988126166
2016;22332654083326698129142
127(11):23902654083326295111143170185197
1509–1512.26022654083326296132169200230261291303
50.4252753085367287
Goyal52727540834685116149164
G,70627540834659
Shah78127540833472104142
MV,93827540835793102
Call10552754083427490105
TG117527540833577
et126827540833558
al.13412754083334962
Efficacy1418275408334527088120153185219
of165227540833958
biological17252754083415694110148188203235268283
agents202427540833372107145167194
in223427540831654
the23032754083246297
treatment24152754083244579111133191226264286
of271627540833958
Erdheim-Chester279027540833455934252854083387388145168211249284310334367389
disease.8292854083385379114146173208220
Br106428540833557
J1136285408324
Haematol.117628540834476111169201223260276289
2018;148028540833468100131143
183:16392854083346599110
520–524.176528540833467101139173206238250
51.4252953085367082
Franconieri5222954083365689127159196234250284305321
F,85829540833642
Deshayes91629540834884111148181212246273
S,120429540833649
de126829540834277
Boysson136029540833977109136162201239
H1614295408348
et167729540833860
al.17522954083365164
Superior183129540833674113149170185223245
efficacy2091295408338567492124157189223
and232929540833573112
similar245729540832944102117132164185
safety26582954083306382116138172
of284529540834161
double42530540833876114154169204
dose64530540834078104139
anakinra80030540833472104134150188209242
in105830540831654
Erdheim-Chester11283054083345593131166181239261304342377404427461482
disease16253054083405682117149175210
after18503054083345378112133
single19983054083284381120135170
dose218430540834078105140
treatment.23393054083234579111133191226264285299
Oncoimmunology26533054083498812015717223042531540835795133171187225265297
2018;73731540833469100131143
7(8):8963154083345084102114
e1450712.10253154083346495128162195227257269
doi:13103154083387691104
10.1080/2162402X.2018.1450712.14293154083346678109140176211236271302333366398434467507520556591622653667698729761796828861891903
52.4253253085367187
Dagna52732540834981120158190
L,73332540833448
Corti79632540834380102127142
A,95332540834459
Langheim102732540833468106145183218233291
S1333325408336
et138432540833760
al.14593254083355063
Tumor153832540833569127165187
necrosis174032540834176108130167194208234
factor19903254083215587111148170
α2175325408340
as223132540833561
a2308325408335
master235832540835790116139173194
regulator25683254083235897135150182204241263
of284632540834060
inflammation425335408315537087119177235267289304342381
in82133540831351
Erdheim-Chester8873354083315290128163179236259302339374401424458479
disease:13823354083365178113144171206218
rationale1616335408319527489127165198213248
for18793354083175576
the19713354083205893
treatment20793354083204276108129187223261282
of237733540833555
patients24473354083377092107142180201229
with26913354083496587126
infliximab.28323354083135142534540831734498095153185225237
J678345408324
Clin7173454083405570108
Oncol84034540834786118155171
2012;102634540833468100130143
30(28):11843454083346988122156174186
e286–e290.138534540833468102137175212246280316329
53.4253553085367186
Ferrero5263554083316687109143164201
E,74235540833245
Belloni8023554083347085100138177192
D,100935540834455
Corti10803554083387597121137
A1232355408340
et128735540833457
al.13593554083314659
TNF-alpha143335540833278111132164180219257289
in173835540831351
Erdheim-Chester18043554083325391129164179237259302340375402425459480
disease22993554083375278113145172207
pericardial25213554083387394110142175196234249281297
effusion283335540833352425365408318578398136175
promotes6153654083385996155193215249275
endothelial90636540833371110148170208243259274306321
leakage12423654083144981111145184219
in147636540831451
vitro1543365408330466990127
and168636540833069108
is180936540831440
neutralized186436540833772109132153186202217246280319
by219936540833769
infliximab.2283365408314516986101132147205237277289
Rheumatology2588365408334721071452032352572944253754083155393125
(Oxford).5653754083186596118155177215235245
2014;82637540833468100131143
53(1):9843754083346785117131143
198–200.11433754083346499136167202238250
54.4253853085367388
Goyal52838540834684116149164
G,70738540834659
Shah78238540833472104142
MV,93938540835693101
Call10563854083417489105
TG117638540833477
et126838540833658
al.13413854083344962
Efficacy1419385408334526987119152184218
of165238540833958
biological17263854083405694110148187202234267283
agents202438540833372107145167195
in223438540831654
the23043854083236196
treatment24153854083244579111133191226264286
of271638540833958
Erdheim-Chester278938540833556944253954083387388145168211249284310334367389
disease.8293954083385379114146173208220
Br106439540833557
J1136395408324
Haematol117639540834476111169201223260276
2018;146739540833468100131143
183(3):16263954083346599117151168180
520–524.182139540833467101139173206238251
55.4254053085367185
Cohen-Aubart52540540834582120155193216257294333366387412
F,95240540833743
Maksud101040540835992122151188227
P,125240540834044
Emile131240540833794110125160
J-F14874054083285185
et158840540833860
al.16644054083365164
Efficacy1744405408337547290122155187221
of198040540834261
infliximab2056405408319577592107138153211243282
in235440540831957
the24264054083266499
treatment25414054083264781113135193228266288
of284440540834261
Erdheim-Chester4254154083335492130165180238260303341376403426459481
disease.9214154083385379114146173208220
Ann115641540834179117
Rheum128941540833573108146204
Dis15084154083466187
2018;161141540833468100131143
77:17694154083346979
1387–1390.18634154083346499132164195225258294307
56.4254253085367288
Jia5284254083223769
X,61342540833649
Ning6774254083435896135
X,82742540833649
Bai8924254083336681
Q988425408345
et104842540833254
al.11184254083294558
Combination119142540833875133172188225258279295333371
of157842540833554
adalimumab164742540833069101116131189227285317356
with20184254083496487125
lower215842540831351102137158
dose233142540833674101136
of248242540833554
methylprednisolone2552425408355901121501811972362582923314254354083385379117133171209244
in68543540831452
Erdheim-Chester7524354083325391129164179237259302340375402425459480
disease12474354083385379114146173208
with14704354083506588126
systemic16114354083265885109142200215247
involvement.18744354083145283121136169203261296334356369
Acta22584354083417296129
Oncol.240243540834786118155171183
2017;26014354083336799129138
56(5):27554354083336887120138150
753–756.42544540833467100136168201235248
57.4254553085367180
Haroche5204554083447798135168206241
J,77645540832436
Amoura82845540834199137175196229
Z,107245540833851
Charlotte113945540834077110131147185207231265
F1419455408332
et146745540833456
al.15384554083324760
Imatinib161445540831472104126142179194234
mesylate186345540835792119152168200222255
for21344554083185677
platelet-derived22274554083385486108142157192214234275309331346379413453
growth26954554083385996147172210
factor4254654083185082105141162
receptor-beta-positive6014654083185183116154175211232251290325346378400439476502516538553584618
Erdheim-Chester12334654083305087124158173229251292329363389412445465
histiocytosis.1713465408334487496111148179212236272298312337350
Blood20784654083324784122160
2008;22534654083316499134145
111(11):2413465408331588499129156170181
5413–5415.26094654083316595124159192226256285296
58.4254753085367288
Montella52847540835392130152185201216248
L,79247540832943
Insabato8504754083135178111150183205242
L,110747540833043
Palmieri11664754083336581138153188209225
G.140647540834256
Imatinib147847540831371103125140178193232
mesylate172547540835691118150166199220254
for19944754083175576
cerebral20864754083296384118158179212228
Langerhans’-cell232947540833063101140175196235267305331344365398432447463
histiocytosis.280747540833651774254854083223775108141166203230244271284
N724485408345
Engl78448540833371110125
J924485408325
Med96448540835489129
2004;110848540833469105141153
351(10):12764854083346798113145176195207
1034–1035.14984854083346699134172202234267300312
59.4254953085367184
Utikal5244954083426580110144159
J,69849540832335
Ugurel74849540834281119140174190
S,95349540833144
Kurzen10124954083337091122156194
H1221495408343
et127949540833255
al.13494954083304658
Imatinib142349540831371103125140178193232
as167049540833157
a1742495408331
treatment17884954083214377109130189224262283
option20874954083357597112150189
for22914954083175476
systemic23824954083255784107141199214246
non-Langerhans2643495408336741131351682022404255054083387394133165203229
cell670505408331658095
histiocytoses.7815054083375278101117155187221246283309344371385
Arch11815054083416293131
Dermatol132850540834580102160192214251267
2007;161050540833569105137147
143(6):17735054083346597115149167179
736–740.196750540833468103141172203239251
60.4255153085367387
Haroche5285154083427495131164201236
J,77951540832234
Charlotte82851540833774106127143181202226260
F,110351540833035
Arnaud11545154083385997129166205
L1374515408329
et141851540833153
al.14865154083304557
High15595154083415694132
prevalence17065154083365791123156171205243275308
of202951540833554
BRAF209851540833369111144
V600E225751540833366101137171
mutations244351540835492114146168183221259285
inErdheim-Chester274351540831249821031414255254083387288145168211248283310333367388
disease8295254083355177112143170205
but10495254083377597
not11625254083357395
in127252540831351
other13385254083355795130151
non-Langerhans150452540833674112135168201239278313334373405443469
cell1989525408329627893
histiocytoses.20975254083355177100115153186219244281308343369383
Blood24955254083334987126165
2012;26765254083326697127140
27;28315254083326574
120(13):4255354083346498118149179196208
2700–2703.64953540833467100136174206239272305317
61.4255453085366981
Haroche52154540834880101139171209244
J,78154540832739
Cohen-Aubart83654540834380118153192214255292331364386410
F,126254540833541
Emile131954540833693108124158
JF149354540832760
et156954540833759
al.16445454083355063
Dramatic172354540834870103161193215230262
efficacy2000545408338567492124157189223
of223854540834160
vemurafenib231354540833570127165186219238273311326365
in269354540831856
both276454540834381103141
multisystemic42555540835795110133148174207234257291348364396
and83655540833170109
refractory960555408320547496129161185222244278
Erdheim-Chester12535554083325391129164180237260303340375402425459480
disease17495554083385379114146172207
and197255540833169108
Langerhans209655540833164102141176198236268306333
cell2444555408331658096
histiocytosis25555554083375278102117155188221246283310324350
harboring4255654083387091131169191207245284
the7245654083226095
BRAF83456540833571114147
V600E99756540833569104141174
mutation.118756540835795117150172187225264277
Blood14795654083355189128168
2013;166256540833468100130141
121(9):18195654083346495110143161173
1495–1500.20075654083346598132169200230264300312
62.4255753085367187
Hyman52757540834678136169207
DM,749575408347102115
Puzanov87957540833774103137175213245
I,113957540831729
Subbiah118457540833371110149165197235
V1434575408337
et148757540833557
al.15605754083334861
Vemurafenib163657540833770128166187220239273311326365
in201757540831654
multiple208657540835996112134149188204239
nonmelanoma234057540833978116174209224257295333391424
cancers2779575408332651034255854083316586113
with5545854083506688126
BRAF69658540833571114147
V60085858540833670105141
mutations.101558540835795117150172187225263290303
N1334585408344
Engl139458540833270109124
J1534585408324
Med157358540835590129
2015;171858540833468100130140
373:187458540833466100112
726–736.200158540833468102140171206240253
63.4255953085367287
Diamond5275954083506597155193232271
EL,8135954083376882
Durham91059540835088109148180238
BH,11635954083408598
Haroche127659540834880102139172210245
J1536595408328
et157959540833961
al.16555954083365164
Diverse17355954083496597131153180215
and196559540833674113
targetable20945954083255879117152175207247263297
kinase24075954083335088120147182
alterations26045954083365174107129162183199237275301
drive4256054083385975107142
histiocytic5826054083385379102117155188221246261293
neoplasms.89160540833772111151166199225283309323
Cancer122960540834073111143177198
Discov14426054083466187119156188
2016;164660540833468100131143
6:180560540833446
154–165.186660540833565100137168199233245
64.4256153085367489
Emile52961540833088103118153
J-F,697615408322457984
Diamond7976154083425890147186224263
EL,10756154083306275
Hélias-Rodzewicz11666154083417692106138165186223261300330364415430462492
Z1674615408335
et172461540833254
al.17936154083294558
Recurrent186661540833368100138159181215253274
RAS215561540833376110
and228061540832967106
PIK3CA24016154083334883119159202
mutations261861540835592115147169184222260287
in42562540831553
Erdheim-Chester4936254083325392130165180237260303341376402426459481
disease.9896254083385379114146173208220
Blood12246254083355189128168
2014;140762540833468100131143
124:15656254083346496108
3016–3019.168962540833468100131169201236268298309
65.3047553085367185
Cohen-Aubart31475540833774112147184207247284323355376401
F,35635540832935
Emile36135540833087102117152
JF,3780554083215460
Maksud38555540835184113142179217
P408755408333
et41355540833153
al.4203554083304557
Marked42755540835284105135169208
efficacy449855408332506885117149181214
of47275540833554
vemurafenib47965540832963120158178211230264302316355
in51665540831250
suprasellar5231554083236099120153179214229244276296
Erdheim-Chester3047654083335492130165180238260303341376403426459481
disease.3543654083385379114146173208220
Neurology37786540834580118139176192230270302
2014;40956540833468100131143
83(14):4253654083356987118149167179
1294–1296.4447654083346498134171202232266302315
66.3047753085367389
Diamond3151754083476395153191229268
EL,3435754083346579
Durham35297540834785107145177235
BH,3780754083368194
Ulaner3890754083456092130165186
GA40927540834587
et41947540833658
al.4267754083344962
Efficacy434475408334527088120153185218
of45787540833958
MEK46517540835690124
inhibition4791754083165492107146162184199237276
in50827540831654
patients5152754083407394110144183204232
with5399754083526890128
histiocytic3047854083385379102117155188221246261293
neoplasms.33568540833772111151166199225283309323
Nature3694854083457799137158192
2019;39018540833569100131143
567:40608540833468101111
521–524.4186854083356899132166199231244
67.3047953085367179
Euskirchen3142954083316894124140162193231266304
P,34619540833438
Haroche3515954083427496133166204239
J,37699540832235
Emile38199540833188104119154
JF39889540832356
et40599540833255
al.4129954083304659
Complete42039540833875134173189223246279
remission44989540831953111126152179194232270
of47839540833655
critical485495408329516689104136169184
neurohistiocytosis5053954083367110913016820622124727028632435639041545230471054083264167
by312910540833970
vemurafenib.321510540833166123161182215234269307322361373
Neurol360410540834479117138176191
Neuroimmunol381110540834480117138176191249307344382421436
Neuroinflamm426310540834480117138176191229247263296353411
2015;469010540833468100130140
2(2):48461054083345185103115
e78.497610540833467100114
68.30471153085367389
Franconieri31511154083365588126158195234249284305320
F,348711540833541
Martin-Silva354311540835890111136151189212243258273305338
N,389711540834760
de397311540834175
Boyssson406411540833876108135161188226265
H4344115408347
et440611540833760
al.44811154083355063
A.455911540834459
Superior463311540833673112148169184222244
efficacy4892115408337567391123156188222
and512911540833573112
tolerance52561154083256278113134167205237271
of304712540833757
reduced31191254083205493131163197236
doses337112540833775102137164
of355012540833756
vemurafenib362112540833166123161182215234269307322361
plus39971254083385492118
anakinra413012540833169102132148186207240
in438512540831452
Erdheim-Chester44531254083325291129164179236259302340375401425458480
disease:49481254083375279114145172207219
Towards518312540833266117150171209235
the54331254083216095
paradigm30471354083397293126165180219277
of333913540834160
combined341413540833572130169185223258297
targeting37271354083245778117151174189227266
and400813540833573113
immune413613540831876133171209244
therapies.43951354083256499120153192207242269283
Acta469313540834476100133
Oncol484113540835089121158174
Acta503013540834576100133
Oncol.517813540835189121158174187
2016;538013540833872104135147
55(7):30471454083346784119138150
930–930.321314540833467101139174207241254
69.30471553085367285
Haroche31481554083447698135167205240
J,340415540832336
Cohen-Aubart345515540833976115150188210252289328361382407
F,387715540833238
Emile393015540833290105120155
JF410015540832457
et417315540833355
al.42441554083314659
Reproducible431915540833570109130168207245277292331347382
and471615540833270109
sustained48401554083266389112145160198233273
efficacy5128155408334527088120153185218
of536215540833656
targeted5433155408321547530471654083387395129169
therapy32311654083246297118151190221
with34681654083526890128
vemurafenib361216540833368126163184217236271309324363
in399016540831755
patients40601654083417496111146184205233
with43081654083536891129
BRAF(V600E)-mutated445216540833874117150168206240275311345365388446484507539561595634
Erdheim-Chester5102165408334559313116618223926230534237740430471754083225577
disease.31391754083385379114146173208220
J3374175408324
Clin34141754083405570108
Oncol353717540834786118155171
2015;372317540833468100130141
33(5):38791754083346785119137149
411–4118.40431754083356593125162193220251265
70.30471853085367186
Schirmer314818540833466104119140198234255
JH,34181854083257083
Thorns351618540833373111132171197
C,372918540834053
Moosig379818540835593132159174212
F4026185408333
et407418540833557
al.41461854083334861
Treatment42231854083335084116138196231269291
failure4529185408319536883120142176
by472018540833971
canakinumab480618540833265103135165182220257315347387
in520818540831553
a5276185408333
patient53241854083397294109144182203
with30471954083516689127
progressive31891954083386097137158192219245260293327
multisystemic353119540835795110132148174206233257290348363395
Erdheim-Chester39421954083325391129164179237259302340375402425459480
disease44371954083385379114146172207
refractory4660195408320547395128160184221243277
to495219540832158
anakinra:502619540833169101131148186207240252
successful5293195408326639512616018721330472054083185772
use31352054083376398
of324820540833857
vemurafenib.332020540833266124162183216235269307322362374
Rheumatology370920540833674109147205237259296312350389421
(Oxford)41462054083186596117155177215234
2015;439620540833468100130141
54(10):45522054083346989120152170182
1932–1934.47492054083356598130164195225258294306
71.30472153085367183
Tzoulis31452154083345996134149164190
C,335121540834053
Schwarzlmüller342021540833365103154187208238254312349365380415436
T,387121540833443
Gjerde39292154083446095116154189
IO413321540831664
et421221540833557
al.42852154083324861
Excellent43612154083336697131146161196234256
response46322154083225683122160199225260
of490821540833857
intramedullary4980215408316547597130187222262300315330362383417
Erdheim-Chester5413215408333549230472254083387388145168211249284310334367389
disease34512254083385379114146173208
to367422540832259
vemurafenib:374822540833166124161182215234269307322361373
a4137225408332
case41842254083316490125
report.43252254083205594133154179192
BMC453222540833691131
Res46792254083357097
Notes479122540834583105139166
2015;497222540833468100130141
8:512822540833447
171.51902254083346496105
72.30472353085367288
Oneal315023540834887122154169
PA,33342354083367488
Kwitkowski343723540833685101123154191242269299315
V,376823540833645
Luo382823540833269108
L3951235408332
e3998235408335
al.40482354083334861
FDA412523540833378117
Approval425823540834181120142179211244259
Summary:453323540833370128186218240274287
Vemurafenib483523540833770128165186219238273311326365
for52152354083195779
the53092354083226196
Treatment54202354083335085304724540833254112147185206
of326924540833756
Patients33402454083356789104139177198226
with35812454083506689127
Erdheim-Chester37232454083325391129164180237260303340375402425459480
Disease42192454083456086121153180215
with44492454083506688126
the45912454083215994
BRAFV600470124540833571114146184218254290
Mutation.500624540835492115147169185222261274
Oncologist.52952454083478611815517120930472554083385379103116
2018;317825540833468100131143
23(12):33372554083346987118148166178
1520–1524.35302554083356598132170201231264296308
73.30472653085367490
Diamond315426540835168102161202242283
EL,34542654083387186
Subbiah355726540833877118159177210250
V,382426540834152
Lockhart389326540833675110142183217240266
AC417626540834687
et428026540833964
al.43612654083375468
Vemurafenib444726540834075135174197232252288328345386
for48502654083246386
BRAF495326540834179124158
V600-mutant512826540834177114152177238277301336376399
Erdheim-Chester30472754083335696137174191251276321361398427453489512
disease35762754083466391129163191229
and382227540833979121
Langerhans396027540833975115156193217257292332361
cell43382754083397592109
histiocytosis:44652754083456290115133173208244271310339356384398
analysis488127540833979114131165194211239
of513827540834466
data522127540834680104139
from53772754083265090150
the304728540832263101
histology-independent,31662854083456291117157175216258293318336377419456498537578620657698722738
phase392128540834788123153190
2,412928540834257
open-label420328540834688126167192211246288326344
VE-BASKET456528540834480104144188225262299337
study.492028540833359100142176189
JAMA512628540833275134179
Oncol.532228540835597132172190205
2018;304729540833470104136150
4:321429540833650
384–388.328129540833672110149183220257272
74.30473053085366884
Cohen314630540834481119154193
Aubart335430540834481121154175199
F,356930540833642
Emile362630540833694109124159
J-F,3800305408328518591
Carrat39063054083447798120153174
F4096305408336
et414730540833860
al.42223054083365164
Targeted43013054083366486124159181215254
therapies45713054083256398119152191207242268
in485530540831856
54492630540833873
patients50153054083427597112147185206234
with52643054083547092131
Erdheim-Chester5410305408336579530473154083387489148171215254290317341375397
disease,34603154083445986122155182218230
including37063154083205991107146185201240280
follow-up4001315408324637995134186209248288
after43053154083385783117139
interruption44603154083205981115137159198238261277316355
(the48313154083244584120
LOVE496731540833784120155
study).51383154083325694134167186197
Blood53513154083415796136176
2017;304732540833468100129139
130:32023254083346498111
1377–1380.33293254083346496130163194224258293306
75.30473353085367085
Bhatia314733540833675107129144176
A,333833540834256
Hatzoglou34093354083457899130167207222260298
V,372333540833645
Ulaner37833354083456092130165186
G3985335408344
et404433540833557
al.41173354083324860
Neurologic419333540834580118139176192230270285317
and452533540833371110
oncologic465033540833877109146162200239254286
features49523354083195385107145166200227
of519433540833858
Erdheim-52673354083335492130165180238260
-Chester304734540832164102137163187220242
disease:33043454083375279114145172207219
a3539345408331
30-patient35853454083346993133166187203237276297
series.3897345408326618298132159173
Neuro408534540834479117138175
Oncol427634540834685117154170
2020446134540833468101135
Jan46113454083235694
17.47203454083346369
pii:4804345408338546981
noaa008.490034540833776109141176213248261
doi:51773454083377591103
10.1093/52953454083346578109140175208232
neuonc/noaa008.304735540833873110148187219246283321354386422458493507
76.30473653085367085
Grob314736540834163100139
JJ,33013654083224657
Amonkar337436540833896134172202235256
MM,3645365408352107120
Karaszewska37803654083326687119146175209260287316349
B.414536540833245
Comparison420636540833774132170203224240265303342
of456336540833454
dabrafenib463236540833567106128160179213251266305
and495236540832967106
trametinib50733654083194073130165187202240255294
combination53823654083296512330473754083395492124146161199238
therapy33003754083236196118151190221
with35363754083526890129
vemurafenib368037540833367125163184217236270308323362
monotherapy405837540835897135174195234269290323362393
on446737540833877
health-related455937540833974106121144182204226260276308330364403
quality497737540834077110125140163196
of518937540833857
life5262375408316315085
in536237540831654
patients54313754083407330473854083223772110131159
with32213854083526790128
unresectable33643854083387697131158193226250283322338373
or375238540833860
metastatic382738540835893115148175198231252268300
cutaneous41423854083327092125163198237275301
BRAF445938540833672115148
Val600-mutation-positive46223854083366883118154190214273310333365387403441479501541580607622644660692726
melanoma536438540835893108141304739540833876134166
(COMBI-v):322939540832363108163199215237270288300
results35453954083255986123139161189
of374939540834262
a3826395408337
phase387839540833978110136171
3,406539540833951
open-label,413139540834382118156178195227266302317330
randomised44763954083265997136174232247273308348
trial.4839395408327496496112124
Lancet497939540833670108140174196
Oncol519039540835291123160176
2015;538139540833974105135146
16(13):30474054083346584116146163175
1389–1398.32374054083346499133171201231265300313
77.30474153085367281
Al314341540834662
Bayati322041540834174105138159175
A,341041540834660
Plate34864154083405587109142
T,364441540833746
Al370641540834661
Bayati378341540834073104137159174
M3972415408360
et404741540833962
al.41244154083375265
Dabrafenib420541540835082122143176195230268283322
and454341540833674114
Trametinib46724154083385588146181203219256272311
Treatment49984154083385589121143201236274296
for53094154083246183
Erdheim-Chester5407415408338599730474254083387388145168211249284310334367389
Disease34514254083486490125157183218
With36854254083607699137
Brain38374254083396093108146
Stem39984254083365791149
Involvement.41624254083185687125141173207265300338360373
Mayo455142540835790120158
Clin47244254083435973111
Proc48514254083385996129
Innov49954254083185694132164
Qual517442540835088121136
Outcomes.532642540835088111141178304743540835792119133
2018;319543540833468100131143
2(3):33544354083345185102114
303–308.348343540833469102138171205241254
78.30474453085367187
Sanders314944540833063101140175196223
IM,33874454083136881
Goodman348344540834280119158216248286
A,378444540833953
Kurzrock38524454083337091121143180213243
R.411044540833347
Real41734454083336899115
word430344540834886107145
toxicity44634454083205787102134149171205
experience468344540833263103138159175209247280313
with50114454083486486124
BRAF/MEK515144540833369111144166220253288
inhibitors54554454083125030474554083385392107130167188215
in327845540831452
pacients334645540833871103119153191213241
with36024554083506688127
Erdheim-Chester37444554083335492130165180238260303341376403426459481
disease.42404554083385379114146173208220
The447545540833372107
Oncologist459745540834786118155171209249264290313
2019;492545540833569101131143
24:50844554083346678
1–5.517745540833467101113
79.30474653085367184
Campochiaro314646540833770127166204237274289321342378
C,353946540833850
Cavalli360546540833769100133148163178
G,379846540834154
Farina3867465408330598095132164
N4046465408342
et410346540833254
al.41724654083294457
Efficacy4244465408330476583114147179212
and447146540832967105
improved459146540831370108130167198232271
tolerability48774654083195672106127160198214229243265299
of519146540833453
combination52594654083296612316217721524730474754083223775113
therapy31764754083205893115148187218
with34094754083506688126
interleukin-135504754083145273107128144179217247263301324355
blockade39204754083375391124154188227262
and419747540833169108
MAPK432047540835496131166
pathway45014754083387192131181214245
inhibitors47614754083145190105144159182219240267
for50444754083175576
the51364754083205893
treatment52454754083204276108129188223261282
of304748540833757
Erdheim-Chesterdisease.31194854083375896134169184242264307345380407430464485523538564599631658693705
Ann383948540834684122
Rheum397648540834078113151209
Dis.42004854083506592105
2019432048540833973105135
Dec447048540835085118
9.460448540833849
pii:4668485408343597486
annrheumdis-2019-216610.476948540833775113134172207245303342357383404435469501531555586617648684714746758
doi:30474954083387692104
10.1136/annrheumdis-2019-21661031664954083346678109137167201226257295333354392427465523562577603624655689721751775806837868904934966
80.30475053085367388
Fernández-Eulate31505054083336788127159197236271301323357393409441463496
G,366250540834458
Muñoz-Lopetegi373550540835593131169197219252289329364387420460475
A,422550540834256
Ruiz42965054083367489118
I4430505408315
et446050540833557
al.45325054083334861
Vemurafenib460850540833769127165186219238272311326365
as498850540833259
first-line5062505408318355683106126142157195230
therapy53075054083226196117150189220
in304751540831553
BRAF-V600E-mutant311551540834077120153174210244279315349371430467490523561582
Erdheim-Chester37135154083385997135170185243266308346381408432465487
disease42155154083435985120152178213
with44445154083557194132
CNS459151540834590123
involvement.47295154083205889127143175210268303341363376
BMJ512051540834196122
Case525751540834578105140
Rep541251540834176115
2019;304752540833468100130143
12(11).32055254083356482113141156166
pii:3387525408338546981
e228280.348452540833368103136170204239251
doi:37515254083387691104
10.1136/bcr-2018-228280.38705254083346678109137166201226266299320340371405437468490521556590623657692705
81.30475353085367082
Van314453540833667105
Keerberghen326553540833469104125165201222260298333371
CA,36515354083408397
Harrouk37635354083447798120157195225
A,400453540834055
Leone407453540833165104143178
L.426753540833145
A4327535408341
new438453540833772123
role45235354083205873108
for46475354083185677
fluorine-18-fluorodeoxyglucose4739535408317347211013214718522024327430532834636340043946049753757261164167571372876630475454083316895130
positron-emission319254540834079106120143164202240262299357372398425439477516
tomography/computed372354540832360118157196217250289328359382411448506545583606639679
tomography441754540832360118157196217250290328359
in479154540831654
Erdheim-Chester48605454083345593131166181239261304342377404427461482
disease.5357545408339558111614830475554083266173
World313655540835793115131170
J3321555408324
Nucl336155540834482114129
Med.350655540835489129142
2019;366355540833569100131143
18(2):38225554083346584118136148
201–203.398555540833468100133164199232244
82.30475653085367390
Akin31545654083447694133
EA,33045654083357995
Osman341556540835079138172211
M,364356540835772
Ellenbogen37325654083355268104144184225266302341
AL.40905654083447792
FDG419956540833581128
PET/CT434456540833871108131172209
Findings45695654083365291132148188228256
of484156540834061
Erdheim-Chester49195654083355897137173189249272317356392421445480503
Disease:54395654083486530475754083276498127165179
Radiologic324457540834378119137177195236278295330
Response359157540834380110151192233262300
to390857540832968
a3994575408339
Novel405057540834889123160178
Treatment42455754083405996130154215253294317
Regimen.458057540834380122139200238278293
Clin48915754083476582122
Nucl503157540835292127144
Med.5193575408362100142157
2018;536757540834279113146160
43(5):30475854083346888123142156
337–340.321958540833670104138171208245259
83.30475953085367186
Young314859540833367104142181
JR,33445954083225771
Johnson34305954083226098136162200238
GB,36835954083417790
Murphy378859540835189110149188218
RC402159540833373
et410959540833254
al.41785954083294457
(18)F-FDG4250595408316487896129150184228273
PET/CT453859540833365100121160195
in474859540831350
Erdheim-Chester48135954083305189127161176234256298336371397420454475
Disease:53035954083425884118150176211223
Imaging304760540831571103141156193232
Findings32936054083304482120135172210236
and354360540832967105
Potential36636054083326889122160181196227242
BRAF392060540833268110142
Mutation407760540835188110142164178216253
Biomarker.43456054083334885142174194224258279289
J4648605408322
Nucl468560540834178110125
Med.482460540835286125138
2018;49766054083326596127138
59(5):51296054083316382115133144
774–779.52886054083316595131162196229239
84.30476153085367489
Rehák315161540833873112144174
Z,334061540834154
Koukalová340961540833875114144177193231263296
R,372061540833852
Vašina37876154083397096111149181
J3984615408327
et402661540833759
al.41006154083355063
18F-FDG417861540833768101123157202247
PET/CT444061540833870106127166202
obraz465761540834080102135164
Erdheimovy-Chesterovy48366154083365795133168183241279311345367410448483510533567588625657691
nemoci304762540833873130169201217
–3279625408335
přehled33296254083396094132148183222
českých35676254083316491121155186224
pacientů.380762540833871104119153191213251263
Nukl.408562540834583113129142
Med.424362540835489129142
20;44006254083346881
7:449762540833444
50–56.455662540833468106140175188